JP2023518038A5 - - Google Patents

Info

Publication number
JP2023518038A5
JP2023518038A5 JP2022555643A JP2022555643A JP2023518038A5 JP 2023518038 A5 JP2023518038 A5 JP 2023518038A5 JP 2022555643 A JP2022555643 A JP 2022555643A JP 2022555643 A JP2022555643 A JP 2022555643A JP 2023518038 A5 JP2023518038 A5 JP 2023518038A5
Authority
JP
Japan
Prior art keywords
amino acid
modified polypeptide
coronavirus
cov
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022555643A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518038A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/022611 external-priority patent/WO2021188576A1/en
Publication of JP2023518038A publication Critical patent/JP2023518038A/ja
Publication of JP2023518038A5 publication Critical patent/JP2023518038A5/ja
Pending legal-status Critical Current

Links

JP2022555643A 2020-03-16 2021-03-16 改変されたアンジオテンシン変換酵素2(ace2)またはその使用 Pending JP2023518038A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062989976P 2020-03-16 2020-03-16
US62/989,976 2020-03-16
US202063022151P 2020-05-08 2020-05-08
US63/022,151 2020-05-08
US202063042907P 2020-06-23 2020-06-23
US63/042,907 2020-06-23
US202063089895P 2020-10-09 2020-10-09
US63/089,895 2020-10-09
PCT/US2021/022611 WO2021188576A1 (en) 2020-03-16 2021-03-16 Modified angiotensin-converting enzyme 2 (ace2) and use thereof

Publications (2)

Publication Number Publication Date
JP2023518038A JP2023518038A (ja) 2023-04-27
JP2023518038A5 true JP2023518038A5 (cg-RX-API-DMAC7.html) 2024-02-29

Family

ID=75439530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022555643A Pending JP2023518038A (ja) 2020-03-16 2021-03-16 改変されたアンジオテンシン変換酵素2(ace2)またはその使用

Country Status (8)

Country Link
US (1) US20230193235A1 (cg-RX-API-DMAC7.html)
EP (1) EP4121170A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023518038A (cg-RX-API-DMAC7.html)
KR (1) KR20220154796A (cg-RX-API-DMAC7.html)
AU (1) AU2021239879A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018527A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174683A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021188576A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116057176A (zh) * 2020-03-21 2023-05-02 赖瑞克斯生物科技公司 Ace2和补体途径的双特异性和三特异性功能分子及其用途
EP3884957A1 (en) * 2020-03-26 2021-09-29 The University of British Columbia Methods for treatment of virus and methods for screening of anti-virus reagent using organoids
US20230257726A1 (en) * 2020-05-11 2023-08-17 Chan Zuckerberg Biohub, Inc. Ace2 compositions and methods
EP4168541A4 (en) 2020-05-20 2025-04-02 Emmune, Inc. Ace2 muteins and methods of using the same
IL276627A (en) * 2020-08-10 2022-03-01 Yeda Res & Dev Compositions for diagnosis and treatment of coronavirus infections
EP4244369A4 (en) * 2020-11-12 2024-10-16 Shanghaitech University GENOME EDITING OF IMPROVED EFFICIENCY AND ACCURACY
EP4426825A4 (en) * 2021-11-01 2025-10-01 Agency Science Tech & Res RECOMBINANT/FUSION POLYPEPTIDES COMPRISING A MUTATED ANGIOTENSIN 2-CONVERTING ENZYME (ACE2)
WO2023081958A1 (en) * 2021-11-11 2023-05-19 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd Antiviral agent comprising a cellular entry receptor and fc region component
CN114606219B (zh) * 2022-04-01 2023-10-31 北京大学 一种冠状病毒中和效应蛋白及其应用
CA3257654A1 (en) * 2022-04-13 2023-10-19 Paradigm Immunotherapeutics, Inc. METHODS OF PREVENTION OR TREATMENT OF RESPIRATORY VIRUS INFECTION, PARTICULARLY SARS-CoV-2
CN117304317B (zh) * 2022-06-28 2024-08-02 四川大学 Ace2受体特异性结合肽及其应用
EP4386084A1 (en) * 2022-12-14 2024-06-19 Formycon AG Improved ace2 fusion proteins
WO2024215776A1 (en) * 2023-04-10 2024-10-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Recombinant ace2 polypeptide and uses thereof
KR20240177843A (ko) * 2023-06-20 2024-12-30 주식회사 엔큐라젠 SARS-CoV-2스파이크 단백질에 특이적으로 결합하는 펩타이드 및 이의 용도
CN117447609B (zh) * 2023-10-25 2026-05-15 山西锦波生物医药股份有限公司 灭活冠状病毒的融合蛋白及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101961493A (zh) * 2002-06-19 2011-02-02 大学保健网 Ace2激活用于治疗心脏、肺和肾脏疾病及高血压
US20130210726A1 (en) * 2012-02-10 2013-08-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of peripheral vascular disease

Similar Documents

Publication Publication Date Title
CN115244077B (zh) 蛋白质治疗剂
IL321500A (en) Pre-stabilized hmpv f proteins
JP2023518038A (ja) 改変されたアンジオテンシン変換酵素2(ace2)またはその使用
JP7554837B2 (ja) 可溶性ace2及び融合タンパク質、並びにその適用
US20230174611A1 (en) Compositions and methods for preventing or reducing the effects of infections by coronaviruses that bind the extracellular domain of the ace2 receptor
CN105934249A (zh) 用于治疗肺高压的组合物和方法
EP4217370A2 (en) Methods and compositions for treating coronaviral infections
WO2021247675A1 (en) Coronavirus-binding agents and uses thereof
JP2025170319A (ja) Sars-cov-2阻害剤
JP2007526213A (ja) コロナウイルスによる感染症の治療、管理および予防用の抗ウイルス剤
WO2024229151A2 (en) Multimeric coronavirus binding molecules and uses thereof
WO2022037699A1 (en) Engineered ace2 oligomers and uses thereof
US20240025972A1 (en) Methods for modulating host cell surface interactions with sars-cov-2
TW201902920A (zh) 重組robo2蛋白、組合物、方法及其用途
US20170198014A1 (en) Polypeptides and their use for treating influenza
CN117659181A (zh) 针对sars-cov-2刺突蛋白的肽治疗剂
JP2024516605A (ja) コロナウイルス感染を処置するための新規組成物及び方法
RU2837537C1 (ru) Растворимый апф2, его слитый белок и способы их применения
ZA200509512B (en) Antiviral agents for the treatment, control and prevention of infections by coronaviruses
WO2022034588A1 (en) Compositions for diagnosis and treatment of coronavirus infections
HK40107422A (en) Methods for modulating host cell surface interactions with sars-cov-2
WO2025230768A1 (en) Compositions and methods related to coronavirus therapies
WO2022146154A2 (en) Peptide for use in the treatment or prevention of covid-19
WO2026062244A1 (en) COMPOSITIONS COMPRISING sTIGIT AND PD-1/PD-L1 AXIS INHIBITORS AND USES THEREOF
HK40080094A (en) Antibody and fusion protein for treating coronaviruses and use thereof